TN-201 gene therapy reduces left ventricular mass and wall thickness in MYBPC3-HCM patients, with five of six achieving NYHA...

Obexelimab met its primary endpoint in Phase 3 IgG4-RD trial with 56% flare risk reduction, prompting FDA BLA submission...

Apalutamide plus ADT reduced metastasis risk by 20% in high-risk prostate cancer, with nine times higher pathologic response than...

FDA accepts Pharming's leniolisib resubmission for children 4-11 with APDS, targeting October 2026 decision after resolving manufacturing documentation issues.

ASCO and Ryght AI are using algorithms to select CDK4/6 inhibitor trial sites. Here's what ops teams need to...

MAMS platform trials could cut neurodegenerative drug timelines—but adaptive stopping rules and FDA guidance gaps threaten to stall the...

DBV Technologies launches THRIVE trial of VIASKIN Peanut Patch in infants ages 6–12 months with confirmed peanut allergy, targeting...

Ziftomenib plus venetoclax/azacitidine achieved 70% composite complete remission in venetoclax-naïve R/R NPM1-mutated AML patients, with rapid response and mana

Obexelimab Phase 3 IgG4-RD trial hits primary endpoint with 56% flare reduction and significant steroid-sparing benefits in largest study...

Nipocalimab shows 58% response rate in autoantibody-positive SLE patients in Phase 2 JASMINE trial, with sustained benefit at Week...